AN2 Therapeutics Ownership 2024 | Who Owns AN2 Therapeutics Now?
Institutional Ownership
65.23%
Insider Ownership
25.36%
Retail Ownership
9.41%
Institutional Holders
45.00
AN2 Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 18.65% | 0.16% | 5,551,295 | - | - | 11,935,284 | Jun 30, 2024 |
| OCTAGON CAPITAL ADVISORS LP | 10.82% | 1.09% | 3,220,263 | 2,117,263 | 191.95% | 6,923,565 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 7.02% | 0.21% | 2,088,889 | 700,000 | 50.40% | 4,491,111 | Jun 30, 2024 |
| TCG CROSSOVER MANAGEMENT, LLC | 5.22% | 0.35% | 1,555,118 | - | - | 3,343,504 | Jun 30, 2024 |
| JANUS HENDERSON GROUP PLC | 4.10% | 0.00% | 1,221,051 | -94 | -0.01% | 2,613,049 | Jun 30, 2024 |
| VANGUARD GROUP INC | 3.50% | - | 1,041,527 | -6,242 | -0.60% | 2,239,283 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 1.77% | 0.00% | 526,352 | 429,438 | 443.11% | 1,131,657 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.05% | 0.00% | 312,615 | - | - | 672,122 | Jun 30, 2024 |
| BLACKROCK INC. | 1.01% | - | 299,703 | 8,617 | 2.96% | 644,362 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.75% | 0.00% | 224,185 | 195,815 | 690.22% | 481,998 | Jun 30, 2024 |
| GHOST TREE CAPITAL, LLC | 0.74% | 0.15% | 219,331 | - | - | 471,562 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.61% | - | 180,923 | 1,553 | 0.87% | 389,098 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.44% | 0.00% | 132,088 | 37,920 | 40.27% | 283,989 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.35% | 0.01% | 104,292 | 78,000 | 296.67% | 224,228 | Jun 30, 2024 |
| ALYESKA INVESTMENT GROUP, L.P. | 0.34% | 0.00% | 100,000 | - | - | 215,000 | Jun 30, 2024 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | 0.33% | 0.01% | 98,278 | - | - | 211,298 | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | 0.33% | 0.00% | 97,063 | 47,456 | 95.66% | 208,685 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.32% | 0.00% | 96,111 | 13,613 | 16.50% | 206,639 | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | 0.31% | 0.00% | 92,406 | -40,381 | -30.41% | 198,673 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.29% | 0.00% | 86,948 | -76,548 | -46.82% | 185,000 | Jun 30, 2024 |
AN2 Therapeutics's largest institutional shareholder is RA CAPITAL MANAGEMENT, L.P., holding 18.65% of the company's total share outstanding, currently valued at $11.94M. The top 10 institutional shareholders own together 53.90% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| OCTAGON CAPITAL ADVISORS LP | 10.82% | 1.09% | 3,220,263 | 2,117,263 | 191.95% | 6,923,565 | Jun 30, 2024 |
| TCG CROSSOVER MANAGEMENT, LLC | 5.22% | 0.35% | 1,555,118 | - | - | 3,343,504 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 7.02% | 0.21% | 2,088,889 | 700,000 | 50.40% | 4,491,111 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 18.65% | 0.16% | 5,551,295 | - | - | 11,935,284 | Jun 30, 2024 |
| GHOST TREE CAPITAL, LLC | 0.74% | 0.15% | 219,331 | - | - | 471,562 | Jun 30, 2024 |
| OCCUDO QUANTITATIVE STRATEGIES LP | 0.12% | 0.01% | 35,366 | -2,331 | -6.18% | 76,037 | Jun 30, 2024 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | 0.33% | 0.01% | 98,278 | - | - | 211,298 | Jun 30, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.13% | 0.01% | 38,918 | -1,382 | -3.43% | 83,674 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.35% | 0.01% | 104,292 | 78,000 | 296.67% | 224,228 | Jun 30, 2024 |
| RMB CAPITAL MANAGEMENT, LLC | 0.15% | 0.00% | 45,942 | - | - | 98,775 | Jun 30, 2024 |
| JANUS HENDERSON GROUP PLC | 4.10% | 0.00% | 1,221,051 | -94 | -0.01% | 2,613,049 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.05% | 0.00% | 312,615 | - | - | 672,122 | Jun 30, 2024 |
| ALYESKA INVESTMENT GROUP, L.P. | 0.34% | 0.00% | 100,000 | - | - | 215,000 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.44% | 0.00% | 132,088 | 37,920 | 40.27% | 283,989 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.29% | 0.00% | 86,948 | -76,548 | -46.82% | 185,000 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 1.77% | 0.00% | 526,352 | 429,438 | 443.11% | 1,131,657 | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | 0.31% | 0.00% | 92,406 | -40,381 | -30.41% | 198,673 | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | 0.33% | 0.00% | 97,063 | 47,456 | 95.66% | 208,685 | Jun 30, 2024 |
| PRIVATE ADVISOR GROUP, LLC | 0.08% | 0.00% | 22,500 | - | - | 48,375 | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | 0.07% | 0.00% | 21,774 | 21,774 | 100.00% | 46,814 | Jun 30, 2024 |
The largest AN2 Therapeutics shareholder by % of total assets is OCTAGON CAPITAL ADVISORS LP. The company owns 3.22M shares of AN2 Therapeutics (ANTX), representing 1.09% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| OCTAGON CAPITAL ADVISORS LP | 10.82% | 1.09% | 3,220,263 | 2,117,263 | 191.95% | 6,923,565 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 7.02% | 0.21% | 2,088,889 | 700,000 | 50.40% | 4,491,111 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 1.77% | 0.00% | 526,352 | 429,438 | 443.11% | 1,131,657 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.75% | 0.00% | 224,185 | 195,815 | 690.22% | 481,998 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.35% | 0.01% | 104,292 | 78,000 | 296.67% | 224,228 | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | 0.33% | 0.00% | 97,063 | 47,456 | 95.66% | 208,685 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.44% | 0.00% | 132,088 | 37,920 | 40.27% | 283,989 | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | 0.07% | 0.00% | 21,774 | 21,774 | 100.00% | 46,814 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.05% | 0.00% | 14,300 | 14,300 | 100.00% | 30,745 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.32% | 0.00% | 96,111 | 13,613 | 16.50% | 206,639 | Jun 30, 2024 |
| MORGAN STANLEY | 0.06% | - | 17,461 | 13,297 | 319.33% | 37,541 | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | 0.04% | 0.00% | 12,825 | 12,825 | 100.00% | 27,574 | Jun 30, 2024 |
| BLACKROCK INC. | 1.01% | - | 299,703 | 8,617 | 2.96% | 644,362 | Jun 30, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.02% | 0.00% | 5,406 | 4,293 | 385.71% | 11,623 | Jun 30, 2024 |
| ROYAL BANK OF CANADA | 0.01% | - | 2,812 | 2,812 | 100.00% | 6,000 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.61% | - | 180,923 | 1,553 | 0.87% | 389,098 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.00% | - | 1,020 | 1,020 | 100.00% | 2,193 | Jun 30, 2024 |
| FEDERATED HERMES, INC. | 0.00% | - | 917 | 706 | 334.60% | 1,972,000 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.05% | - | 15,636 | 664 | 4.43% | 33,617 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.00% | - | 250 | - | - | 537 | Jun 30, 2024 |
As of Jun 30 2024, AN2 Therapeutics's largest institutional buyer is OCTAGON CAPITAL ADVISORS LP. The company purchased 2.12M stocks of ANTX, valued at $6.92M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BVF INC/IL | - | - | - | -1,239,470 | -100.00% | - | Jun 30, 2024 |
| AVIDITY PARTNERS MANAGEMENT LP | - | - | - | -1,150,000 | -100.00% | - | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.29% | 0.00% | 86,948 | -76,548 | -46.82% | 185,000 | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | - | - | - | -76,200 | -100.00% | - | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | - | - | - | -43,814 | -100.00% | - | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | 0.31% | 0.00% | 92,406 | -40,381 | -30.41% | 198,673 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.03% | - | 10,186 | -40,179 | -79.78% | 21,900 | Jun 30, 2024 |
| XTX TOPCO LTD | - | - | - | -38,666 | -100.00% | - | Jun 30, 2024 |
| BARCLAYS PLC | - | - | - | -28,318 | -100.00% | - | Jun 30, 2024 |
| HRT FINANCIAL LP | - | - | - | -24,366 | -100.00% | - | Jun 30, 2024 |
| CHICAGO PARTNERS INVESTMENT GROUP LLC | - | - | - | -22,001 | -100.00% | - | Jun 30, 2024 |
| SWISS NATIONAL BANK | - | - | - | -20,575 | -100.00% | - | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.08% | - | 25,150 | -12,965 | -34.02% | 54,073 | Jun 30, 2024 |
| ATOM INVESTORS LP | - | - | - | -11,905 | -100.00% | - | Jun 30, 2024 |
| CLEAR STREET MARKETS LLC | - | - | - | -10,000 | -100.00% | - | Jun 30, 2024 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | - | - | - | -9,251 | -100.00% | - | Jun 30, 2024 |
| VANGUARD GROUP INC | 3.50% | - | 1,041,527 | -6,242 | -0.60% | 2,239,283 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.11% | - | 32,595 | -3,768 | -10.36% | 70,079,000 | Jun 30, 2024 |
| OCCUDO QUANTITATIVE STRATEGIES LP | 0.12% | 0.01% | 35,366 | -2,331 | -6.18% | 76,037 | Jun 30, 2024 |
| UBS GROUP AG | 0.06% | - | 17,483 | -2,091 | -10.68% | 37,588 | Jun 30, 2024 |
As of Jun 30 2024, AN2 Therapeutics's biggest institutional seller is BVF INC/IL. The company sold -1.24M shares of ANTX, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SCHONFELD STRATEGIC ADVISORS LLC | 0.07% | 0.00% | 21,774 | 21,774 | 100.00% | 46,814 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.05% | 0.00% | 14,300 | 14,300 | 100.00% | 30,745 | Jun 30, 2024 |
| ROYAL BANK OF CANADA | 0.01% | - | 2,812 | 2,812 | 100.00% | 6,000 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.00% | - | 1,020 | 1,020 | 100.00% | 2,193 | Jun 30, 2024 |
AN2 Therapeutics's largest new institutional shareholder by number of shares is SCHONFELD STRATEGIC ADVISORS LLC, purchased 21.77K shares, valued at $46.81K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BVF INC/IL | - | - | - | -1,239,470 | -100.00% | - | Jun 30, 2024 |
| AVIDITY PARTNERS MANAGEMENT LP | - | - | - | -1,150,000 | -100.00% | - | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | - | - | - | -76,200 | -100.00% | - | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | - | - | - | -43,814 | -100.00% | - | Jun 30, 2024 |
| XTX TOPCO LTD | - | - | - | -38,666 | -100.00% | - | Jun 30, 2024 |
| BARCLAYS PLC | - | - | - | -28,318 | -100.00% | - | Jun 30, 2024 |
| HRT FINANCIAL LP | - | - | - | -24,366 | -100.00% | - | Jun 30, 2024 |
| CHICAGO PARTNERS INVESTMENT GROUP LLC | - | - | - | -22,001 | -100.00% | - | Jun 30, 2024 |
| SWISS NATIONAL BANK | - | - | - | -20,575 | -100.00% | - | Jun 30, 2024 |
| ATOM INVESTORS LP | - | - | - | -11,905 | -100.00% | - | Jun 30, 2024 |
| CLEAR STREET MARKETS LLC | - | - | - | -10,000 | -100.00% | - | Jun 30, 2024 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | - | - | - | -9,251 | -100.00% | - | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -128 | -100.00% | - | Jun 30, 2024 |
AN2 Therapeutics's largest sold out institutional shareholder by shares sold is BVF INC/IL, sold -1.24M shares, valued at -, as of undefined.
AN2 Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| VANGUARD VALLEY FORGE FUNDS | 0.02% | 11,822 | - | - | Mar 31, 2024 |
| BRIDGEWAY FUNDS INC | 0.01% | 23,792 | -10,700 | -31.02% | Mar 28, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.00% | 1,841 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.00% | 15,732 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 1,011,352 | -271,633 | -21.17% | Mar 31, 2024 |
| VICTORY PORTFOLIOS | 0.00% | 34,110 | - | - | Mar 31, 2024 |
| ETF Managers Trust | 0.00% | 7,541 | -725 | -8.77% | Dec 31, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 163,156 | 73,515 | 82.01% | Feb 29, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 138,557 | -64,895 | -31.90% | Jan 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 17,261 | - | - | Mar 31, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 173,377 | -12,012 | -6.48% | Feb 29, 2024 |
| Amplify ETF Trust | 0.00% | 7,654 | 7,654 | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 8,550 | -21,348 | -71.40% | Jan 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 481 | - | - | Mar 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 4,491 | - | - | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 348 | - | - | Mar 31, 2024 |
| Global X Funds | 0.00% | 5,522 | - | - | Jan 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 3,400 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 5,608 | - | - | Mar 28, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 116 | - | - | Mar 31, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 2,927 | 2,865 | 4620.97% | Jan 31, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 88,194 | - | - | Mar 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 457 | - | - | Feb 29, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 40,060 | - | - | Feb 29, 2024 |
| VALIC Co I | 0.00% | 4,089 | - | - | Feb 29, 2024 |
| ProFunds | 0.00% | 141 | - | - | Mar 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 1,573 | - | - | Mar 31, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 46 | - | - | Dec 31, 2023 |
| RYDEX SERIES FUNDS | 0.00% | 42 | - | - | Dec 31, 2023 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 1,116 | -4,175 | -78.91% | Feb 29, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 200 | - | - | Mar 28, 2024 |
| PROSHARES TRUST | 0.00% | 1,313 | - | - | Feb 29, 2024 |
| TIAA-CREF FUNDS | 0.00% | 15,065 | - | - | Mar 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 428 | - | - | Feb 29, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 8,900 | - | - | Mar 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 1,273 | - | - | Mar 31, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 3 | - | - | Dec 31, 2023 |
| EQ ADVISORS TRUST | 0.00% | 1,597 | -1,897 | -54.29% | Mar 31, 2024 |
| iSHARES TRUST | 0.00% | 21,415 | -564 | -2.57% | Mar 31, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 1,196 | - | - | Mar 31, 2024 |
| ETF Series Solutions | 0.00% | 23 | - | - | Jan 31, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 756 | - | - | Jan 31, 2024 |
| Bridge Builder Trust | 0.00% | 3,310 | - | - | Mar 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 1,808 | - | - | Mar 31, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 1,580 | - | - | Mar 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 460 | -2,444 | -84.16% | Mar 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 1,126 | - | - | Feb 29, 2024 |
AN2 Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 11.82K shares, compromising 0.02% of its total assets.
AN2 Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 45 | -16.67% |
| 31 Mar, 24 | 54 | 5.88% |
| 31 Dec, 23 | 51 | 37.84% |
| 30 Sep, 23 | 37 | 19.35% |
| 30 Jun, 23 | 31 | -16.22% |
| 31 Mar, 23 | 37 | 5.71% |
| 31 Dec, 22 | 35 | - |
| 30 Sep, 22 | 35 | 2.94% |
| 30 Jun, 22 | 34 | 88.89% |
| 31 Mar, 22 | 18 | - |
As of 30 Jun 24, 45 institutions are holding AN2 Therapeutics's shares, representing a decrease of -16.67% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 19,415,909 | 3.64% |
| 31 Mar, 24 | 18,733,564 | -8.13% |
| 31 Dec, 23 | 20,391,503 | 2.31% |
| 30 Sep, 23 | 19,931,490 | 69.75% |
| 30 Jun, 23 | 11,741,514 | 22.30% |
| 31 Mar, 23 | 9,600,249 | -1.66% |
| 31 Dec, 22 | 9,762,609 | 2.80% |
| 30 Sep, 22 | 9,496,733 | 1.17% |
| 30 Jun, 22 | 9,386,991 | 4.85% |
| 31 Mar, 22 | 8,952,737 | - |
AN2 Therapeutics (ANTX) has 19.42M shares outstanding as of 30 Jun 24, up 3.64% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 65.23% | 1.04% |
| 31 Mar, 24 | 79.38% | 1.26% |
| 31 Dec, 23 | 79.51% | 0.76% |
| 30 Sep, 23 | 102.23% | 2.79% |
| 30 Jun, 23 | 60.57% | 2.47% |
| 31 Mar, 23 | 49.52% | 1.95% |
| 31 Dec, 22 | 50.45% | 2.09% |
| 30 Sep, 22 | 49.09% | 2.07% |
| 30 Jun, 22 | 48.74% | 2.26% |
| 31 Mar, 22 | 46.49% | - |
As of 30 Jun 24, AN2 Therapeutics is held by 65.23% institutional shareholders, representing a 1.04% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 20 | -35.48% |
| 31 Mar, 24 | 31 | -3.13% |
| 31 Dec, 23 | 32 | 23.08% |
| 30 Sep, 23 | 26 | 136.36% |
| 30 Jun, 23 | 11 | -52.17% |
| 31 Mar, 23 | 23 | -14.81% |
| 31 Dec, 22 | 27 | 58.82% |
| 30 Sep, 22 | 17 | -37.04% |
| 30 Jun, 22 | 27 | 50.00% |
| 31 Mar, 22 | 18 | - |
20 institutional shareholders have increased their position in ANTX stock as of 30 Jun 24 compared to 31 in the previous quarter (a -35.48% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 13 | -18.75% |
| 31 Mar, 24 | 16 | 60.00% |
| 31 Dec, 23 | 10 | 25.00% |
| 30 Sep, 23 | 8 | -50.00% |
| 30 Jun, 23 | 16 | 128.57% |
| 31 Mar, 23 | 7 | 133.33% |
| 31 Dec, 22 | 3 | -72.73% |
| 30 Sep, 22 | 11 | 175.00% |
| 30 Jun, 22 | 4 | - |
| 31 Mar, 22 | - | - |
13 institutional shareholders have reduced their position in ANTX stock as of 30 Jun 24 compared to 16 in the previous quarter (a -18.75% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 45 | -16.67% | 19,415,909 | 3.64% | 65.23% | 1.04% | 20 | -35.48% | 13 | -18.75% |
| 31 Mar, 24 | 54 | 5.88% | 18,733,564 | -8.13% | 79.38% | 1.26% | 31 | -3.13% | 16 | 60.00% |
| 31 Dec, 23 | 51 | 37.84% | 20,391,503 | 2.31% | 79.51% | 0.76% | 32 | 23.08% | 10 | 25.00% |
| 30 Sep, 23 | 37 | 19.35% | 19,931,490 | 69.75% | 102.23% | 2.79% | 26 | 136.36% | 8 | -50.00% |
| 30 Jun, 23 | 31 | -16.22% | 11,741,514 | 22.30% | 60.57% | 2.47% | 11 | -52.17% | 16 | 128.57% |
| 31 Mar, 23 | 37 | 5.71% | 9,600,249 | -1.66% | 49.52% | 1.95% | 23 | -14.81% | 7 | 133.33% |
| 31 Dec, 22 | 35 | - | 9,762,609 | 2.80% | 50.45% | 2.09% | 27 | 58.82% | 3 | -72.73% |
| 30 Sep, 22 | 35 | 2.94% | 9,496,733 | 1.17% | 49.09% | 2.07% | 17 | -37.04% | 11 | 175.00% |
| 30 Jun, 22 | 34 | 88.89% | 9,386,991 | 4.85% | 48.74% | 2.26% | 27 | 50.00% | 4 | - |
| 31 Mar, 22 | 18 | - | 8,952,737 | - | 46.49% | - | 18 | - | - | - |
AN2 Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of AN2 Therapeutics's stock was made by RA CAPITAL MANAGEMENT, L.P. on Aug 13 2024, selling 3,410,335 shares at $1.08 per share (valued at $3.68M). The last insider buy of ANTX was made by Leonard Braden Michael on Aug 14 2024, buying 1,500,000 shares at $1.04 per share (worth $1.56M).
AN2 Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 2 | 2 | 100.00% |
| Q2 2024 | 8 | - | - |
| Q1 2024 | 16 | 15 | 106.67% |
| Q4 2023 | - | 8 | - |
| Q3 2023 | 1 | 28 | 3.57% |
| Q2 2023 | 9 | - | - |
| Q1 2023 | 7 | - | - |
| Q4 2022 | 1 | 22 | 4.55% |
| Q3 2022 | 6 | - | - |
| Q2 2022 | 24 | - | - |
| Q1 2022 | 14 | 30 | 46.67% |
2 total buy trades, and 2 total sell trades (buy/sell ratio of 1.00%) were made by AN2 Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 1 | 2 | 50.00% |
| Q2 2024 | - | - | - |
| Q1 2024 | - | 12 | - |
| Q4 2023 | - | 8 | - |
| Q3 2023 | 1 | 28 | 3.57% |
| Q2 2023 | 1 | - | - |
| Q1 2023 | - | - | - |
| Q4 2022 | - | 22 | - |
| Q3 2022 | 6 | - | - |
| Q2 2022 | 5 | - | - |
| Q1 2022 | 7 | - | - |
As of Q3 2024, Insider owners conducted 1 open market buy trades and 2 open market sell trades of AN2 Therapeutics's stocks.
AN2 Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| PMVP | PMV Pharmaceuticals, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| MNOV | MediciNova, Inc. |
| PHVS | Pharvaris N.V. |
| RZLT | Rezolute, Inc. |
| PEPG | PepGen Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| MOLN | Molecular Partners AG |
| ELYM | Eliem Therapeutics, Inc. |
ANTX Ownership FAQ
Who Owns AN2 Therapeutics?
AN2 Therapeutics is owned by institutional shareholders (65.23%), insiders (25.36%), and public (9.41%). The largest institutional shareholder of AN2 Therapeutics is RA CAPITAL MANAGEMENT, L.P. (18.65% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.02% of total shares).
Who are the major institutional shareholders of AN2 Therapeutics?
AN2 Therapeutics's major institutional shareholders are RA CAPITAL MANAGEMENT, L.P., OCTAGON CAPITAL ADVISORS LP, FRAZIER LIFE SCIENCES MANAGEMENT, L.P., TCG CROSSOVER MANAGEMENT, LLC, and JANUS HENDERSON GROUP PLC. The top five shareholders own together 45.82% of the company's share outstanding.
How many AN2 Therapeutics shareholders are there?
As of Jun 2024, there are 45 institutional shareholders of AN2 Therapeutics.
What percentage of AN2 Therapeutics is owned by RA CAPITAL MANAGEMENT, L.P?
RA CAPITAL MANAGEMENT, L.P owns 5.55M shares of AN2 Therapeutics, representing 18.65% of the company's total shares outstanding, valued at $11.94M (as of Jun 2024).
What percentage of AN2 Therapeutics is owned by OCTAGON CAPITAL ADVISORS LP?
As of Jun 2024, OCTAGON CAPITAL ADVISORS LP holds 3.22M shares of AN2 Therapeutics (ANTX), compromising 10.82% of the company, valued at $6.92M.
What percentage of AN2 Therapeutics is owned by FRAZIER LIFE SCIENCES MANAGEMENT, L.P?
FRAZIER LIFE SCIENCES MANAGEMENT, L.P is the third largest holder of AN2 Therapeutics. The company owns 2.09M of the company's shares outstanding (worth $4.49M).